期刊文献+

安宫黄体酮治疗晚期乳腺癌 被引量:2

A CLINICAL TRIAL OF MEDROXYPROGESTERONE IN THE TREATMENT OF ADVANCED BREAST CANCER
下载PDF
导出
摘要 30例晚期乳腺癌患者试用安宫黄体酮肌注治疗,剂量为200mg,每日两次。6例CR,9例PR,有效率50%。平均缓解时间6个月,至今持续缓解时间在1年以上者1人,达4年者1人。在其它内分泌药物无效或失效时,亦可试用。除肌注部位产生硬块外,其它副作用不大。 Medroxyprogesterone was used intramuscularly in thirty advanced breast cancer patients. The dosage was 200mg twice daily. 6 patients achieved CR, 9 patients PR. Responst rate was 50% . Average duration of remission was 6 months, with one patient longer than one year, one patient up to four years. Side effects were mild except induration at the site of injection.
作者 赵体平
出处 《癌症》 SCIE CAS CSCD 北大核心 1990年第3期182-184,共3页 Chinese Journal of Cancer
  • 相关文献

参考文献2

  • 1Richard Poulin,Denis Baker,Donald Poirier,Fernand Labrie. Androgen and glucocorticoid receptor-mediated inhibition of cell proliferation by medroxyprogesterone acetate in ZR-75-1 human breast cancer cells[J] 1989,Breast Cancer Research and Treatment(2):161~172
  • 2Mario Lena,Cristina Brambilla,Pinuccia Valagussa,Gianni Bonadonna. High-dose medroxyprogesterone acetate in breast cancer resistant to endocrine and cytotoxic therapy[J] 1979,Cancer Chemotherapy and Pharmacology(3):175~180

同被引文献10

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部